Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 plus durvalumab after chemoradiotherapy for KRAS G12C-mutant locally advanced unresectable non-small cell lung cancer
2025-522038-29-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 plus durvalumab with Placebo plus durvalumab (2 arms). Primary endpoint: Progression-Free Survival. Planned start Jun 2026; status: authorised.
02
Drugs
calderasibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522038-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522038-29-00.